- Home
- PFD vs TLSI Comparison
PFD vs TLSI Comparison
Compare PFD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- TLSI
- Stock Information
- Founded
- PFD 1990
- TLSI 2010
- Country
- PFD United States
- TLSI United States
- Employees
- PFD N/A
- TLSI N/A
- Industry
- PFD Investment Managers
- TLSI Medical Specialities
- Sector
- PFD Finance
- TLSI Health Care
- Exchange
- PFD Nasdaq
- TLSI Nasdaq
- Market Cap
- PFD 144.5M
- TLSI 160.4M
- IPO Year
- PFD N/A
- TLSI N/A
- Fundamental
- Price
- PFD $11.27
- TLSI $5.50
- Analyst Decision
- PFD
- TLSI Strong Buy
- Analyst Count
- PFD 0
- TLSI 6
- Target Price
- PFD N/A
- TLSI $11.75
- AVG Volume (30 Days)
- PFD 33.2K
- TLSI 68.4K
- Earning Date
- PFD 01-01-0001
- TLSI 03-27-2025
- Dividend Yield
- PFD 6.30%
- TLSI N/A
- EPS Growth
- PFD N/A
- TLSI N/A
- EPS
- PFD N/A
- TLSI N/A
- Revenue
- PFD N/A
- TLSI $29,431,000.00
- Revenue This Year
- PFD N/A
- TLSI $55.43
- Revenue Next Year
- PFD N/A
- TLSI $50.09
- P/E Ratio
- PFD N/A
- TLSI N/A
- Revenue Growth
- PFD N/A
- TLSI 58.99
- 52 Week Low
- PFD $8.53
- TLSI $3.50
- 52 Week High
- PFD $11.18
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- PFD 50.39
- TLSI 51.83
- Support Level
- PFD $11.14
- TLSI $5.23
- Resistance Level
- PFD $11.35
- TLSI $5.72
- Average True Range (ATR)
- PFD 0.09
- TLSI 0.34
- MACD
- PFD -0.00
- TLSI 0.01
- Stochastic Oscillator
- PFD 54.17
- TLSI 76.60
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.